SK6172000A3 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
SK6172000A3
SK6172000A3 SK617-2000A SK6172000A SK6172000A3 SK 6172000 A3 SK6172000 A3 SK 6172000A3 SK 6172000 A SK6172000 A SK 6172000A SK 6172000 A3 SK6172000 A3 SK 6172000A3
Authority
SK
Slovakia
Prior art keywords
substituted
heteroaryl
defined above
alkyl
group
Prior art date
Application number
SK617-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SK6172000A3 publication Critical patent/SK6172000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK617-2000A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration SK6172000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Publications (1)

Publication Number Publication Date
SK6172000A3 true SK6172000A3 (en) 2001-03-12

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
SK617-2000A SK6172000A3 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (ko)
JP (1) JP2001521891A (ko)
KR (1) KR20010031577A (ko)
CN (1) CN1278178A (ko)
AR (1) AR043071A1 (ko)
AU (1) AU1206799A (ko)
BG (1) BG104436A (ko)
BR (1) BR9813318A (ko)
CA (1) CA2307850A1 (ko)
HU (1) HUP0100012A3 (ko)
IL (1) IL135518A0 (ko)
NO (1) NO20002189L (ko)
PL (1) PL340604A1 (ko)
SK (1) SK6172000A3 (ko)
TR (1) TR200001147T2 (ko)
WO (1) WO1999022722A2 (ko)
ZA (1) ZA989885B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5037771B2 (ja) 2000-04-13 2012-10-03 バイオチカ テクノロジー リミテッド グリコシル化されたハイブリッド産物およびその産生方法と利用
EP1539157B1 (en) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2520732C (en) 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
CN1950388A (zh) * 2004-02-27 2007-04-18 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US8470985B2 (en) 2005-08-24 2013-06-25 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
US8278281B2 (en) 2005-08-24 2012-10-02 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
KR20010031577A (ko) 2001-04-16
JP2001521891A (ja) 2001-11-13
HUP0100012A2 (hu) 2001-05-28
CN1278178A (zh) 2000-12-27
BG104436A (en) 2000-12-29
WO1999022722A3 (en) 1999-08-05
HUP0100012A3 (en) 2003-07-28
EP1027060A2 (en) 2000-08-16
TR200001147T2 (tr) 2000-08-21
NO20002189L (no) 2000-06-28
ZA989885B (en) 1999-05-05
WO1999022722A2 (en) 1999-05-14
BR9813318A (pt) 2000-08-22
AR043071A1 (es) 2005-07-20
CA2307850A1 (en) 1999-05-14
NO20002189D0 (no) 2000-04-27
IL135518A0 (en) 2001-05-20
PL340604A1 (en) 2001-02-12
AU1206799A (en) 1999-05-24

Similar Documents

Publication Publication Date Title
SK6172000A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
AU2014203882B2 (en) Methods for reducing cellular proliferation and treating certain diseases
EP0929563B1 (en) 6-o-substituted ketolides having antibacterial activity
WO2007016656A2 (en) Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
JP2000505469A (ja) 新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用
EA016653B1 (ru) Способы и композиции для ингибирования ангиогенеза
KR20140139083A (ko) 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
JP2836964B2 (ja) １６員環マクロライド系抗生物質の誘導体
KR0179379B1 (ko) 4"-데옥시에리트로마이신 유도체
JP2023109937A (ja) ３－置換１，２，４－オキサジアゾールの結晶形態
EP1025114B1 (en) 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity
CN1269803A (zh) 6,9－桥红霉素衍生物
CA2367319A1 (en) Erythromycin derivatives
JPH08508038A (ja) １６員環マクロライド系抗生物質のアミド誘導体
JPH07110874B2 (ja) エリスロマイシンａ誘導体
US6946446B2 (en) Anti-infective agents useful against multidrug-resistant strains of bacteria
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
JP2004529921A (ja) ロイコマイシンから誘導された９−アミノ−１４員環マクロライド
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
EP2852601A1 (en) Semisynthetic derivatives of nystatin a1
EP1259923B1 (en) Anti-infective agents useful against mulitidrug-resistant strains of bacteria
JPH06507407A (ja) エリスロマイシン誘導体
JP2020509086A (ja) トリアゾール含有マクロライド及びその眼科的使用
JP2020511445A (ja) ドライアイ疾患を治療するための組成物および方法